Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease
This study has been completed.
Sponsor:
S.L.A. Pharma AG
Information provided by:
S.L.A. Pharma AG
ClinicalTrials.gov Identifier:
NCT00774969
First received: October 16, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the blood levels of Metronidazole after application to the peri anal area after a single dose and 6 or 7 days application.
| Condition | Intervention | Phase |
|---|---|---|
|
Perianal Crohns' |
Drug: Metronidazole |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Primary Purpose: Basic Science |
| Official Title: | Phase 1 Study to Evaluate the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri-Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease |
Resource links provided by NLM:
Genetics Home Reference related topics:
Crohn disease
MedlinePlus related topics:
Crohn's Disease
U.S. FDA Resources
Further study details as provided by S.L.A. Pharma AG:
| Enrollment: | 19 |
| Study Start Date: | October 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: All
6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
|
Drug: Metronidazole
Metronidazole 10% ointment three times a day 7 days
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Patient group:
- Male and female patients with Crohn's disease (diagnosed by radiology, endoscopy and pathology), with anorectal involvement.
- Aged 18-65 years.
- Have had perianal symptoms for longer than 2 months
- Have a score of 5 or above in the Perianal Crohn's Disease Activity Index (PCDAI)
- Have a score of 1 or above on the 'Type of perianal disease' assessment of the PCDAI
Subjects can be on concomitant medication. Acceptable regimens are:
- Aminosalicylates at a dosage that has been stable for more than 4 weeks before screening;Infliximab on a stable infusion regimen;
- Oral corticosteroids <40mg per day; Methotrexate, provided that dosage has been stable for more than 4 weeks; azathioprine or mercaptopurine at a dosage that has been stable for more than 8 weeks;
- Antibiotics at a dosage that has been stable for 4 weeks but excluding metronidazole.
- Cyclosporin on a stable dose for more than 4 weeks.
- If patients have setons these must have been in place for at least 4 weeks prior to screening.
- If female, the subject must not be lactating and must be (a) post-menopausal, (b) surgically sterilised, or (c) have a negative pregnancy test result prior to entry into the study and will use double-barrier methods of contraception (two separate methods of birth control, one of which may include oral contraception) for the duration of the study.
- Must have provided written informed consent to participate.
Healthy volunteer group:
- They have had surgery to the anus or rectum in the past 4 weeks.
- Have a history of inflammatory bowel disease.
- Allergic to metronidazole.
- Are taking any prohibited medication.
- Not prepared to refrain from drinking alcohol during the course of the study.
- Deemed mentally incompetent.
- Considered by their physician unlikely to be able to comply with the protocol.
- Has donated blood within the past 3 months.
- Taken part in an experimental drug study in the preceding three months.
Exclusion Criteria:
Patient group:
- They have had surgery to the anus or rectum in the past 4 weeks.
- They have a perianal abscess requiring incision and drainage.
- They have a stoma of less than 6 months duration.
- Allergic to metronidazole.
- Are taking any prohibited medication.
- Not prepared to refrain from drinking alcohol during the course of the study.
- Deemed mentally incompetent.
- Considered by their physician unlikely to be able to comply with the protocol.
- Has donated blood within the past 3 months.
- Taken part in an experimental drug study in the preceding three months.
- Has donated blood within the past 3 months.
- Taken part in an experimental drug study in the preceding three months.
Healthy volunteer group:
- They have had surgery to the anus or rectum in the past 4 weeks.
- Have a history of inflammatory bowel disease.
- Allergic to metronidazole.
- Are taking any prohibited medication.
- Not prepared to refrain from drinking alcohol during the course of the study.
- Deemed mentally incompetent.
- Considered by their physician unlikely to be able to comply with the protocol.
- Has donated blood within the past 3 months.
- Taken part in an experimental drug study in the preceding three months.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00774969
Locations
| United Kingdom | |
| Sainsbury Wing, St Marks & Northwick Park Hospitals, Watford Road | |
| Harrow, United Kingdom, HA1 3UJ | |
Sponsors and Collaborators
S.L.A. Pharma AG
Investigators
| Study Director: | Christopher J Jordan, BSC | SLA Pharma |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00774969 History of Changes |
| Other Study ID Numbers: | MET/PK/01, EudraCT/IND 2007003173-68 |
| Study First Received: | October 16, 2008 |
| Last Updated: | October 16, 2008 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Additional relevant MeSH terms:
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Metronidazole |
Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Infective Agents Therapeutic Uses Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on June 18, 2013